Loading…
Loading…
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference ca.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights five areas: Scaling genomic interpretation with AI and machine learning: A GeneDx.
Shares of GeneDx Holdings Corp. (NASDAQ: WGS - Get Free Report) were down 5.5% during mid-day trading on Friday. The company traded as low as $66.92 and last traded at $66.3710. Approximately 32,972 shares changed hands during trading, a decline of 96% from the average session volume of 919,692 shares. The stock had previously closed at
LifeMD (NASDAQ: LFMD - Get Free Report) and GeneDx (NASDAQ: WGS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability. Profitability This table compares LifeMD and GeneDx's net margins,
Brookdale Senior Living (NYSE: BKD - Get Free Report) and GeneDx (NASDAQ: WGS - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk. Analyst Ratings This is a breakdown of
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new findings to be presented
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026.